Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model  

OracleBio presented a poster at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), on Sunday 2nd April in Washington D.C. The poster, made in collaboration with E-Therapeutics, is entitled ‘Evaluation of ETS2101 in Combination with anti-mCTLA4 Monoclonal Antibody on CD4 and CD8 TILs in a Subcutaneous CT-26 Colorectal Cancer Model’ and is provided in full below

Click to view or download the poster

The poster shows data from a study in which immunohistochemistry (IHC) was used in combination with digital image analysis to quantify CD4+ and CD8+ Tumor Infiltrating Lymphocytes (TILs) in  subcutaneous colorectal cancer tumours (CT-26)  treated with ETS2101 in combination with an anti-mCTLA4 checkpoint inhibitor. The study demonstrates how IHC combined with image analysis can be utilized to evaluate therapeutic response on TILs within the context of their tumor microenvironment.

To find out more about OracleBio’s digital image analysis services, please contact us.

 

To keep up to date with all OracleBio news and publications, please follow us on LinkedIn by clicking the button below: